Want to see PTIX full AI Analyst Report?
PTIX Stock Chart & Stats
$0.57
-$0.02(-2.65%)
At close: 4:00 PM EST
$0.57
-$0.02(-2.65%)
Day’s Range― - ―
52-Week Range$0.20 - $6.20
Previous CloseN/A
Volume99.44K
Average Volume (3M)102.28K
Market Cap
$416.35K
Enterprise Value$1.69M
Total Cash (Recent Filing)$2.21M
Total Debt (Recent Filing)$3.16M
Price to Earnings (P/E)―
Beta-2.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,810,208
10 Day Avg. Volume80,054
30 Day Avg. Volume102,276
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market Cap4.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-44.69
Enterprise Value/Ebitda-0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAdvancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.
Innovative Therapeutic ApproachA unique therapeutic mechanism can create a competitive advantage in treating CNS disorders, enhancing market position and long-term growth prospects.
Intellectual Property StrengthSecuring patents strengthens the company's intellectual property portfolio, protecting innovations and supporting long-term competitive positioning.
Bears Say
Financial InstabilityPersistent financial losses and lack of revenue highlight challenges in achieving financial stability, increasing reliance on external funding.
Negative Cash FlowNegative cash flow from operations indicates unsustainable financial practices, potentially limiting the company's ability to fund R&D and growth.
Deteriorating EquityDecreasing equity reflects weakening financial health, which could hinder the company's ability to invest in future growth opportunities.
Protagenic Therapeutics News
PTIX FAQ
What was Protagenic Therapeutics’s price range in the past 12 months?
Protagenic Therapeutics lowest stock price was $0.20 and its highest was $6.20 in the past 12 months.
What is Protagenic Therapeutics’s market cap?
Protagenic Therapeutics’s market cap is $416.35K.
When is Protagenic Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Protagenic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Protagenic Therapeutics overvalued?
According to Wall Street analysts Protagenic Therapeutics’s price is currently Overvalued.
Does Protagenic Therapeutics pay dividends?
Protagenic Therapeutics does not currently pay dividends.
What is Protagenic Therapeutics’s EPS estimate?
Protagenic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagenic Therapeutics have?
Protagenic Therapeutics has 1,810,208 shares outstanding.
What happened to Protagenic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Protagenic Therapeutics?
Currently, no hedge funds are holding shares in PTIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
3.69% Other Institutional Investors
96.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---